Clinical Trial Update: COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating a COVID-19 vaccine booster dosing in patients with hematologic malignancies has completed enrollment and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Al Amyloidosis
• Chronic Lymphocytic Leukemia
• Multiple Myeloma

Snippet

Sponsor: Barbara Ann Karmanos Cancer Institute | Conditions: Multiple Myeloma, AL Amyloidosis | Phase 2 | Status: COMPLETED | Results posted: 2023-11-18